Kodiak Sciences Inc
NASDAQ:KOD
Kodiak Sciences Inc
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Palo Alto, California and currently employs 93 full-time employees. The company went IPO on 2018-10-04. The Company’s Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s lead product candidate includes KSI-301, which is an antibody biopolymer conjugate being investigated in multiple pivotal studies in retinal vascular diseases, including wAMD, DME, RVO and non-proliferative diabetic retinopathy. KSI-301 is under Phase IIb/III clinical trials. The Company’s other pipeline candidates includes product candidates KSI-501 and KSI-601, which are developed for the treatment of other unmet needs in retina, such as dry AMD and glaucoma. The Company’s subsidiary includes Kodiak Sciences GmbH.
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Palo Alto, California and currently employs 93 full-time employees. The company went IPO on 2018-10-04. The Company’s Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s lead product candidate includes KSI-301, which is an antibody biopolymer conjugate being investigated in multiple pivotal studies in retinal vascular diseases, including wAMD, DME, RVO and non-proliferative diabetic retinopathy. KSI-301 is under Phase IIb/III clinical trials. The Company’s other pipeline candidates includes product candidates KSI-501 and KSI-601, which are developed for the treatment of other unmet needs in retina, such as dry AMD and glaucoma. The Company’s subsidiary includes Kodiak Sciences GmbH.
Pipeline Progress: Kodiak is advancing three late-stage clinical programs—tarcocimab, KSI-501, and KSI-101—and expects to have four pivotal studies ongoing later in 2024.
Regulatory Alignment: The FDA has agreed that one additional successful pivotal study with the new tarcocimab formulation will be sufficient for approval, and Kodiak is actively enrolling the GLOW2 Phase III trial in diabetic retinopathy.
Portfolio Diversification: KSI-101 offers a new opportunity independent of Kodiak's ABC Platform, targeting macular edema with inflammation—a market with few existing treatment options.
Study Design: The upcoming DAYBREAK Phase III trial in wet AMD will include both tarcocimab and KSI-501 arms, with an aflibercept comparator, aiming for cost-effective, multi-purpose data generation.
Cash Runway: Kodiak states it has a strong cash position to deliver key value inflection points through 2026, including the completion of multiple pivotal trials.
